Clinical Trial Update: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Lemzoparlimab in combination with azacitidine versus azacitidine alone in higher-risk myelodysplastic syndrome has been termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Lemzoparlimab (Lemzoparlimab)

Snippet

Sponsor: TJ Biopharma Co., Ltd. | Conditions: Myelodysplastic Syndromes(MDS) | Phase 3 | Status: TERMINATED